27 July 2026

AstraZeneca results: H1 and Q2 2026

Growth momentum continues. On track to deliver ambition of $80 billion in Total Revenue in 2030

Revenue and EPS summary

	H1 2026	% Change		Q2 2026	% Change	
	$m	Actual	CER[1]	$m	Actual	CER
- Product Sales	*28,896*	*8*	*5*	*14,510*	*5*	*4*
- Alliance Revenue	*1,699*	*31*	*29*	*874*	*34*	*33*
Product Revenue	30,595	9	6	15,384	6	5
Collaboration Revenue	77	(6)	(9)	-	n/m	n/m
Total Revenue	**30,672**	**9**	**6**	**15,384**	**6**	**5**
Reported EPS ($)	**3.60**	**4**	**3**	**1.61**	**2**	**(2)**
Core[2] EPS ($)	**5.21**	**12**	**11**	**2.63**	**21**	**18**

Key performance elements for H1 2026

(Growth numbers at constant exchange rates)

- Total Revenue up 6%, with double-digit growth in Oncology and Rare Disease offsetting headwinds from *Farxiga* US loss of exclusivity and China volume-based procurement
- Core Operating profit and Core EPS increased 11%
- Interim dividend increased 3 cents to $1.06 per share (79.5 pence, 10.32 SEK)
- 30 approvals in major regions since Q4 2025 results

Pascal Soriot, Chief Executive Officer, AstraZeneca, said:

"In the first half we saw strong performance and continued pipeline delivery, including six key positive Phase III programmes and eight first approvals in major markets, including in the US for Baxfendy, our first-in-class medicine for hypertension.

While we are disappointed by the CARDIO-TTRansform outcome, we are on track to deliver our $80bn Total Revenue ambition, which assumes successes and setbacks. We remain confident in the strength of our pipeline and have more than twenty high-value readouts due over the next 18 months.

We continue to invest at pace in our transformative technologies, and in our commercial execution to bring our innovative medicines to patients around the globe and drive growth beyond 2030."

Please click on the below link or refer the associated PDF document to view the full announcement.

http://www.rns-pdf.londonstockexchange.com/rns/9440N_1-2026-7-26.pdf